Study comparing medicines to prevent blood clots in patients with spinal cord injury causing paralysis

Comparison of different deep venous thrombosis pharmacological prophylaxis in paraplegic patients due to spinal cord injury an exploratory trial - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/04/086038

Enrollment

120

Registered

2025-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M45-M49- Spondylopathies

Interventions

Intervention1: Medical drug intervention: Nil Control Intervention1: RIVAROXABAN: NIL Control Intervention2: Aspirin: 150 mg Once a day Per oral for 3 months Control Intervention3: Dabigatran: 110 mg

Eligibility

Inclusion criteria

Inclusion criteria: Patients with ASIA A neurology ASIA B neurology FRENKEL A neurology FRENKEL B neurolog

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To compare efficacy of ASPIRIN , DABIGATRAN AND RIVAROXABAN which can be used as DVT prophylaxis in paraplegic patient with spinal cord injury using components of ultrasound examination of vein viz grey scale ( whether there is compression or not ) and doppler ( whether there is colour filling or not ) using CFV , SFV and poplitealÂ veinÂ screeningTimepoint: at 14 days , 45 days , 90 days postoperatively	—

Measure

Time frame

To compare efficacy of ASPIRIN , DABIGATRAN AND RIVAROXABAN which can be used as DVT prophylaxis in paraplegic patient with spinal cord injury using components of ultrasound examination of vein viz grey scale ( whether there is compression or not ) and doppler ( whether there is colour filling or not ) using CFV , SFV and poplitealÂ veinÂ screeningTimepoint: at 14 days , 45 days , 90 days postoperatively

—

Secondary

Measure	Time frame
To study cost effective analysis between aspirin , dabigatran , rivaroxaban in paraplegic patient due to spinal cord injury To study effect of aspirin , dabigatran and rivaroxaban over CRPH , D-dimer , ESR To compare the outcome of operated patients with time of intervention To find out incidence of DVT in indian population in each ( aspirin , dabigatran and rivaroxabanÂ group)Timepoint: at 14 days , 45 days , 90 days postoperatively	—

Measure

Time frame

To study cost effective analysis between aspirin , dabigatran , rivaroxaban in paraplegic patient due to spinal cord injury To study effect of aspirin , dabigatran and rivaroxaban over CRPH , D-dimer , ESR To compare the outcome of operated patients with time of intervention To find out incidence of DVT in indian population in each ( aspirin , dabigatran and rivaroxabanÂ group)Timepoint: at 14 days , 45 days , 90 days postoperatively

—

Countries

India

Contacts

Public ContactUtsav anand

AIIMS Rishikesh

pankaj.orth@aiimsrishikesh.edu.in8475000282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026